Roscovitine in cancer and other diseases.
Jonas Cicenas(Vilnius University), K. Pavan Kalyan(Vilnius University), Aleksandras Sorokinas(Vilnius University), Edvinas Stankunas(Vilnius University), Josh Levy(Vilnius University), Ingrida Meskinyte(Vilnius University), Vaidotas Stankevičius(Vilnius University), Algirdas Kaupinis(Vilnius University), Mindaugas Valius(Vilnius University)
Cited by 217
Abstract
Roscovitine [CY-202, (R)-Roscovitine, Seliciclib] is a small molecule that inhibits cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a broad-range purine inhibitor, which inhibits CDK1, CDK2, CDK5 and CDK7, but is a poor inhibitor for CDK4 and CDK6. Roscovitine is widely used as a biological tool in cell cycle, cancer, apoptosis and neurobiology studies. Moreover, it is currently evaluated as a potential drug to treat cancers, neurodegenerative diseases, inflammation, viral infections, polycystic kidney disease and glomerulonephritis. This review focuses on the use of roscovitine in the disease model as well as clinical model research.
Related Papers
No related papers found
Powered by citation graph analysis